JP2014520105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520105A5 JP2014520105A5 JP2014513858A JP2014513858A JP2014520105A5 JP 2014520105 A5 JP2014520105 A5 JP 2014520105A5 JP 2014513858 A JP2014513858 A JP 2014513858A JP 2014513858 A JP2014513858 A JP 2014513858A JP 2014520105 A5 JP2014520105 A5 JP 2014520105A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- polymer according
- tumor
- group
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493886P | 2011-06-06 | 2011-06-06 | |
| US61/493,886 | 2011-06-06 | ||
| PCT/AU2012/000647 WO2012167309A1 (en) | 2011-06-06 | 2012-06-06 | Macromolecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520105A JP2014520105A (ja) | 2014-08-21 |
| JP2014520105A5 true JP2014520105A5 (https=) | 2015-07-23 |
| JP6158177B2 JP6158177B2 (ja) | 2017-07-05 |
Family
ID=47295262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513858A Active JP6158177B2 (ja) | 2011-06-06 | 2012-06-06 | 高分子 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9744246B2 (https=) |
| EP (1) | EP2729179B1 (https=) |
| JP (1) | JP6158177B2 (https=) |
| KR (1) | KR101941318B1 (https=) |
| CN (2) | CN103796684B (https=) |
| AU (1) | AU2012267200B2 (https=) |
| BR (1) | BR112013031556B1 (https=) |
| CA (1) | CA2837979C (https=) |
| DK (1) | DK2729179T3 (https=) |
| ES (1) | ES2834992T3 (https=) |
| HR (1) | HRP20201998T1 (https=) |
| HU (1) | HUE052285T2 (https=) |
| IN (1) | IN2014DN00101A (https=) |
| LT (1) | LT2729179T (https=) |
| PL (1) | PL2729179T3 (https=) |
| PT (1) | PT2729179T (https=) |
| SI (1) | SI2729179T1 (https=) |
| WO (1) | WO2012167309A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| WO2014184503A1 (fr) * | 2013-05-16 | 2014-11-20 | Universite De Strasbourg | Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations |
| WO2015035446A1 (en) * | 2013-09-10 | 2015-03-19 | Starpharma Pty Ltd | Macromolecules of dendrimer-platinum conjugates |
| EP3152248B1 (en) | 2014-06-06 | 2019-10-09 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
| CN108135881B (zh) | 2015-08-11 | 2020-11-13 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| CN106554329B (zh) * | 2015-09-26 | 2019-07-05 | 南京友怡医药科技有限公司 | 水溶性紫杉醇抗癌药物化合物及其制备方法和应用 |
| CN106554330B (zh) * | 2015-09-26 | 2019-07-05 | 南京友怡医药科技有限公司 | 水溶性多西他赛抗癌药物化合物及其制备方法和应用 |
| WO2017068051A1 (en) * | 2015-10-21 | 2017-04-27 | Lek Pharmaceuticals D.D. | Peg-based dendron and process for producing the same |
| WO2017135893A1 (en) * | 2016-02-05 | 2017-08-10 | Nipsea Technologies Pte Ltd | Aqueous dendritic amine coatings |
| US20190142953A1 (en) * | 2016-05-10 | 2019-05-16 | Massachusetts Institute Of Technology | Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods |
| TWI773730B (zh) | 2017-02-22 | 2022-08-11 | 瑞典商阿斯特捷利康公司 | 治療性樹枝狀聚合物 |
| JP7249591B2 (ja) * | 2018-03-29 | 2023-03-31 | 日油株式会社 | 分解性ポリエチレングリコール結合体 |
| BR112021000658A2 (pt) * | 2018-07-19 | 2021-04-13 | Starpharma Pty Ltd | Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero |
| US12071517B2 (en) | 2018-07-19 | 2024-08-27 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| TWI856967B (zh) * | 2018-08-17 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| US12514853B2 (en) * | 2018-11-20 | 2026-01-06 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| EP3886912A4 (en) * | 2018-11-29 | 2023-01-04 | Starpharma Pty Limited | DENDRIMER FOR THERAPY AND IMAGING |
| CA3149263A1 (en) * | 2019-08-28 | 2021-03-04 | David Owen | Targeted dendrimer conjugates |
| US20220395525A1 (en) * | 2019-09-26 | 2022-12-15 | Starpharma Pty Ltd | Therapeutic dendrimer |
| TW202206106A (zh) * | 2020-04-24 | 2022-02-16 | 大陸商上海森輝醫藥有限公司 | 一類載藥的大分子及其製備方法 |
| AU2021284918A1 (en) * | 2020-06-03 | 2023-01-05 | Starpharma Pty Ltd | Therapeutic conjugates |
| EP4205767A4 (en) * | 2020-08-25 | 2024-04-10 | Shanghai Senhui Medicine Co., Ltd. | ACTIVE INGREDIENT-LOADED MACROMOLECULE AND PRODUCTION PROCESS THEREOF |
| US20230263900A1 (en) * | 2020-08-31 | 2023-08-24 | Starpharma Pty Ltd. | Dendrimer-drug conjugate |
| TWI910236B (zh) * | 2020-09-24 | 2026-01-01 | 美商視爾普斯眼科公司 | 包含水凝膠及環孢菌素之持續釋放可生物降解淚小管內插入物 |
| EP4216929A1 (en) * | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| CN117164357B (zh) * | 2023-01-03 | 2024-07-19 | 广东捷成科创电子股份有限公司 | 一种五元系大功率型压电陶瓷材料及其制备方法 |
| TW202448514A (zh) * | 2023-05-08 | 2024-12-16 | 大陸商上海森輝醫藥有限公司 | 抗真菌藥的載藥大分子及其製備方法 |
| WO2026046228A1 (zh) * | 2024-08-27 | 2026-03-05 | 苏州拓界医药有限公司 | 树枝状聚合物偶联物及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| CN101102787A (zh) * | 2004-08-09 | 2008-01-09 | 艾丽奥斯生物制药有限公司 | 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法 |
| CN104524596B (zh) | 2006-01-20 | 2018-10-09 | 星药股份有限公司 | 经修饰的大分子 |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| DK2052011T3 (da) * | 2006-08-11 | 2020-12-07 | Starpharma Pty Ltd | Målrettet polylysin-dendrimer-terapeutisk stof |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| WO2011072290A2 (en) * | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| EP2566335B1 (en) * | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
-
2012
- 2012-06-06 BR BR112013031556-3A patent/BR112013031556B1/pt not_active IP Right Cessation
- 2012-06-06 CN CN201280038437.3A patent/CN103796684B/zh active Active
- 2012-06-06 WO PCT/AU2012/000647 patent/WO2012167309A1/en not_active Ceased
- 2012-06-06 CN CN201910456157.8A patent/CN110124051B/zh active Active
- 2012-06-06 KR KR1020147000115A patent/KR101941318B1/ko active Active
- 2012-06-06 LT LTEP12797060.6T patent/LT2729179T/lt unknown
- 2012-06-06 ES ES12797060T patent/ES2834992T3/es active Active
- 2012-06-06 HR HRP20201998TT patent/HRP20201998T1/hr unknown
- 2012-06-06 EP EP12797060.6A patent/EP2729179B1/en active Active
- 2012-06-06 JP JP2014513858A patent/JP6158177B2/ja active Active
- 2012-06-06 HU HUE12797060A patent/HUE052285T2/hu unknown
- 2012-06-06 SI SI201231865T patent/SI2729179T1/sl unknown
- 2012-06-06 CA CA2837979A patent/CA2837979C/en active Active
- 2012-06-06 PL PL12797060T patent/PL2729179T3/pl unknown
- 2012-06-06 US US14/124,651 patent/US9744246B2/en active Active
- 2012-06-06 DK DK12797060.6T patent/DK2729179T3/da active
- 2012-06-06 AU AU2012267200A patent/AU2012267200B2/en active Active
- 2012-06-06 IN IN101DEN2014 patent/IN2014DN00101A/en unknown
- 2012-06-06 PT PT127970606T patent/PT2729179T/pt unknown
-
2017
- 2017-08-28 US US15/688,780 patent/US10265409B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520105A5 (https=) | ||
| JP6158177B2 (ja) | 高分子 | |
| Abolmaali et al. | A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis | |
| KR102811484B1 (ko) | 치료 덴드리머 | |
| Zhou et al. | Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery | |
| Taheri et al. | The in vivo antitumor activity of LHRH targeted methotrexate–human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice | |
| JP6595463B2 (ja) | 気道に影響する増殖性疾患の処置に有用な製剤 | |
| Wong et al. | Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy | |
| CN113613680A (zh) | 用于增强癌症免疫疗法的与免疫检查点抑制剂复合的树枝状聚合物 | |
| Shi et al. | Ascorbic palmitate as a bifunctional drug and nanocarrier of paclitaxel for synergistic anti-tumor therapy | |
| Maji et al. | Polymeric nanomaterials: Fundamentals and therapeutic applications | |
| CN114025743B (zh) | 含有混合聚合物胶束的药物组合物 | |
| Girase et al. | Design of surface tailored carboxymethyl dextran-protein based nanoconjugates for paclitaxel: Spectroscopical characterizations and cytotoxicity assay | |
| Wang et al. | Complete regression of xenografted breast tumors by dextran-based dual drug conjugates containing paclitaxel and docosahexaenoic acid | |
| JP2023500602A (ja) | ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。 | |
| TW201807025A (zh) | 主動標靶型高分子衍生物、包含該高分子衍生物之組合物、及其等之用途 | |
| US12071517B2 (en) | Therapeutic dendrimer | |
| Lather et al. | Polymeric micelles of modified chitosan block copolymer as nanocarrier for delivery of paclitaxel | |
| AU2014215555B2 (en) | Nanoparticles containing a taxane and their use | |
| Gingras et al. | Degradable dendrimers for drug delivery | |
| HK40080640A (en) | Peptide-nanoparticle conjugates | |
| HK40060279A (en) | Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy |